MedPath

Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)

Phase 1
Completed
Conditions
Chronic Asthma
First Posted Date
2008-08-21
Last Posted Date
2024-05-09
Lead Sponsor
Organon and Co
Target Recruit Count
68
Registration Number
NCT00739297

Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Mometasone furoate nasal spray (MFNS)
Drug: Matching placebo nasal spray
First Posted Date
2008-08-12
Last Posted Date
2024-05-21
Lead Sponsor
Organon and Co
Target Recruit Count
351
Registration Number
NCT00732381

A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)

Phase 3
Completed
Conditions
Perennial Allergic Rhinitis
Interventions
First Posted Date
2008-08-12
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
98
Registration Number
NCT00732368

Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Mometasone furoate nasal spray (MFNS)
Drug: Matching placebo nasal spray
First Posted Date
2008-08-12
Last Posted Date
2024-05-21
Lead Sponsor
Organon and Co
Target Recruit Count
324
Registration Number
NCT00733005

Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)

Phase 3
Completed
Conditions
Nasal Polyps
Interventions
First Posted Date
2008-08-08
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
162
Registration Number
NCT00731185

Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)

Completed
Conditions
Hypercholesterolemia
Coronary Heart Disease
Interventions
Drug: Statin
Drug: Ezetimibe
First Posted Date
2008-08-08
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
712
Registration Number
NCT00730132

Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)

Phase 4
Completed
Conditions
Osteoporosis Postmenopausal
Interventions
First Posted Date
2008-08-07
Last Posted Date
2024-04-23
Lead Sponsor
Organon and Co
Target Recruit Count
343
Registration Number
NCT00729651

Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Mometasone furoate nasal spray (MFNS)
Drug: Matching placebo nasal spray
First Posted Date
2008-08-05
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
333
Registration Number
NCT00728416

Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)

First Posted Date
2008-08-01
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
1200
Registration Number
NCT00726856

A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)

Phase 3
Completed
Conditions
Breast Cancer
Interventions
Drug: placebo
Drug: tibolone
First Posted Date
2008-07-30
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
102
Registration Number
NCT00725374
© Copyright 2025. All Rights Reserved by MedPath